DeepMed Research

Shanghai Pharmaceuticals Holding Co.,Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: SPH9788
Drug: Placebo

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-26

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 94

Registration Number: NCT06839131

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: SPH7485

First Posted Date: 2024-07-05

Last Posted Date: 2024-08-07

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 170

Registration Number: NCT06487455

Locations: 🇨🇳
XiangYa Hospital CentralSouth University, Changsha, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, China
🇨🇳
Yunnan Cancer Hospital, Kunming, China

and more 3 locations

A Clinical Study of SPH7854 Granules in Healthy Subjects.

Early Phase 1

Recruiting

Conditions: Inflammatory Bowel Disease

Interventions: Drug: SPH7854
Drug: Placebo

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-03

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 111

Registration Number: NCT06483373

Locations: 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, China

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Phase 2

Recruiting

Conditions: Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

Interventions: Drug: SPH5030

First Posted Date: 2024-05-30

Last Posted Date: 2025-03-12

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 60

Registration Number: NCT06434597

Locations: 🇨🇳
Beijing Friendship Hospital，Capital Medical University, Beijing, China
🇨🇳
Chinese PLA General hospital, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China

and more 27 locations

A Food Effect Study of SPH5030 Tablets.

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: SPH5030

First Posted Date: 2024-04-17

Last Posted Date: 2024-04-17

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 16

Registration Number: NCT06372223

Locations: 🇨🇳
West China Second Hospital ,Sichuan University, Chengdu, China

A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

Early Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: SPH6516 tablets

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 16

Registration Number: NCT06266923

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Biological: T3011 high dose
Biological: T3011 middle dose
Biological: T3011 low dose

First Posted Date: 2024-01-19

Last Posted Date: 2025-03-12

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 68

Registration Number: NCT06214143

Locations: 🇨🇳
Hunan cancer hospital, Changsha, China
🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, China

and more 19 locations

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Phase 1

Recruiting

Conditions: Advanced Melanoma

Interventions: Biological: T3011

First Posted Date: 2024-01-19

Last Posted Date: 2025-04-11

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 42

Registration Number: NCT06214156

Locations: 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳
Beijing Cancer Hospital, Beijing, China

and more 4 locations

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SPH4336
Drug: Cadonilimab

First Posted Date: 2023-07-13

Last Posted Date: 2024-11-28

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 63

Registration Number: NCT05944224

Locations: 🇨🇳
The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

and more 13 locations

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: SPH4336 Tablets

First Posted Date: 2023-06-15

Last Posted Date: 2024-06-17

Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Target Recruit Count: 29

Registration Number: NCT05905614

Locations: 🇨🇳
West China Hospital，Sichuan University, Chengdu, Sichuan, China
🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
🇨🇳
Peking University Cancer Hospital, Beijing, China

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy